<i><scp>HCV E1E</scp>2‐<scp>MF</scp>59</i> vaccine in chronic hepatitis <scp>C</scp> patients treated with <scp>PEG</scp>‐<scp>IFN</scp>α2a and <scp>R</scp>ibavirin: a randomized controlled trial
P. Colombatto(Azienda Ospedaliera Universitaria Pisana), Ferruccio Bonino(Ospedale Santa Chiara), Ludovico Antonio Muratori(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Sergio Abrignani(Istituto Nazionale Genetica Molecolare), Maurizia Rossana Brunetto(University of Pisa), Rino Rappuoli(University of Siena), Mario U. Mondelli(University of Pavia), Maria Grazia Rumi(University of Milan), Michael Houghton(University of Alberta), Antonio Ascione(Ospedale Antonio Cardarelli), Piero Luigi Almasio(University of Palermo), V. Romagnoli(University of Pisa), A.M. Maina(University of Pisa), Domenico Rosa(Novartis (Italy)), Giovambattista Pinzello(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 22
Related Papers
<i>cag</i> , a pathogenicity island of <i>Helicobacter pylori,</i> encodes type I-specific and disease-associated virulence factors
|Proceedings of the National Academy of Sciences|1996|1.9k
Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis
|New England Journal of Medicine|1989|1.7k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661